www.fdanews.com/articles/152625-ben-venue-consent-decree-could-be-signal-on-hospira-analyst-says
Ben Venue Consent Decree Could Be Signal on Hospira, Analyst Says
January 24, 2013
Boehringer Ingelheim subsidiary Ben Venue Laboratories has signed a consent decree to resolve a history of good manufacturing practice (GMP) slipups. The decree would let it continue making some essential drugs while a third party assesses its facilities — a provision analysts say could open the door to a similar decree for Hospira.
Drug Industry Daily
Drug Industry Daily